Biotage AB (BIOT) - Net Assets

Latest as of March 2025: Skr3.85 Billion SEK ≈ $413.89 Million USD

Based on the latest financial reports, Biotage AB (BIOT) has net assets worth Skr3.85 Billion SEK (≈ $413.89 Million USD) as of March 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (Skr4.71 Billion ≈ $506.66 Million USD) and total liabilities (Skr862.00 Million ≈ $92.76 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check Biotage AB PP&E and investment ratio to assess the company's strategic physical and investment asset allocation.

Key Net Assets Metrics

Metric	Value
Current Net Assets	Skr3.85 Billion
% of Total Assets	81.69%
Annual Growth Rate	6.52%
5-Year Change	315.44%
10-Year Change	652.39%
Growth Volatility	30.79

Biotage AB - Net Assets Trend (2000–2024)

This chart illustrates how Biotage AB's net assets have evolved over time, based on quarterly financial data. For live market cap and overall valuation, see Biotage AB (BIOT) total market value.

Annual Net Assets for Biotage AB (2000–2024)

The table below shows the annual net assets of Biotage AB from 2000 to 2024. Also explore BIOT year-over-year net asset growth to track the company's year-over-year net asset growth rate.

Year	Net Assets	Change
2024-12-31	Skr4.11 Billion ≈ $442.62 Million	+12.47%
2023-12-31	Skr3.66 Billion ≈ $393.55 Million	+123.40%
2022-12-31	Skr1.64 Billion ≈ $176.17 Million	+19.31%
2021-12-31	Skr1.37 Billion ≈ $147.65 Million	+38.58%
2020-12-31	Skr990.04 Million ≈ $106.54 Million	+13.08%
2019-12-31	Skr875.50 Million ≈ $94.22 Million	+24.68%
2018-12-31	Skr702.18 Million ≈ $75.57 Million	+15.37%
2017-12-31	Skr608.61 Million ≈ $65.50 Million	+8.06%
2016-12-31	Skr563.24 Million ≈ $60.61 Million	+3.03%
2015-12-31	Skr546.66 Million ≈ $58.83 Million	+8.75%
2014-12-31	Skr502.65 Million ≈ $54.09 Million	+5.43%
2013-12-31	Skr476.77 Million ≈ $51.31 Million	-10.18%
2012-12-31	Skr530.83 Million ≈ $57.13 Million	-5.86%
2011-12-31	Skr563.90 Million ≈ $60.68 Million	-0.71%
2010-12-31	Skr567.95 Million ≈ $61.12 Million	-47.85%
2009-12-31	Skr1.09 Billion ≈ $117.20 Million	-3.18%
2008-12-31	Skr1.12 Billion ≈ $121.05 Million	+41.26%
2007-12-31	Skr796.26 Million ≈ $85.69 Million	+11.76%
2006-12-31	Skr712.47 Million ≈ $76.67 Million	-3.49%
2005-12-31	Skr738.25 Million ≈ $79.45 Million	+41.12%
2004-12-31	Skr523.13 Million ≈ $56.30 Million	-14.17%
2003-12-31	Skr609.50 Million ≈ $65.59 Million	-1.08%
2002-12-31	Skr616.16 Million ≈ $66.31 Million	-21.51%
2001-12-31	Skr784.98 Million ≈ $84.48 Million	-13.01%
2000-12-31	Skr902.36 Million ≈ $97.11 Million	--

Equity Component Analysis

This analysis shows how different components contribute to Biotage AB's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.

Equity Composition Insights

Retained earnings have grown by 153700000000.0% over the analyzed period, indicating profitable operations and earnings retention.

Current Equity Component Breakdown (December 2024)

Component	Amount	Percentage
Retained Earnings	Skr1.54 Billion	37.37%
Common Stock	Skr113.00 Million	2.75%
Other Components	Skr2.46 Billion	59.88%
Total Equity	Skr4.11 Billion	100.00%

Biotage AB Competitors by Market Cap

The table below lists competitors of Biotage AB ranked by their market capitalization.

Company	Market Cap
Herbalife Nutrition Ltd NYSE:HLF	$1.23 Billion
Treehouse Foods Inc NYSE:THS	$1.23 Billion
Xiamen Solex High-Tech Industries Co Ltd SHG:603992	$1.23 Billion
OCI Co Ltd KO:010060	$1.23 Billion
Hoymiles Power Electronics Inc SHG:688032	$1.23 Billion
Grupo Televisa S.A.B. F:TLV	$1.23 Billion
Beijing Urban Construction Investment & Development Co Ltd SHG:600266	$1.23 Billion
Koh Young Technology Inc KQ:098460	$1.23 Billion

Equity Growth Attribution

This analysis shows how different factors contributed to changes in Biotage AB's equity between the two most recent reporting periods.

Equity Growth Insights

From 2023 to 2024, total equity changed from 3,657,000,000 to 4,113,000,000, a change of 456,000,000 (12.5%).
Net income of 284,000,000 contributed positively to equity growth.
Dividend payments of 128,000,000 reduced retained earnings.
Share repurchases of 2,000,000 reduced equity.
New share issuances of 2,000,000 increased equity.
Other comprehensive income increased equity by 124,000,000.
Other factors increased equity by 176,000,000.

Equity Change Factors (2023 to 2024)

Factor	Impact	Contribution
Net Income	Skr284.00 Million	+6.9%
Dividends Paid	Skr128.00 Million	-3.11%
Share Repurchases	Skr2.00 Million	-0.05%
Share Issuances	Skr2.00 Million	+0.05%
Other Comprehensive Income	Skr124.00 Million	+3.01%
Other Changes	Skr176.00 Million	+4.28%
Total Change	Skr-	12.47%

Book Value vs Market Value Analysis

This analysis compares Biotage AB's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.

Valuation Insights

Current price-to-book ratio: 2.79x
The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
The price-to-book ratio has decreased from 13.43x to 2.79x over the analyzed period, indicating reduced market premium.

Historical Price-to-Book Ratios

Date	Book Value per Share	Market Price	P/B Ratio
2002-12-31	Skr10.66	Skr143.20	x
2003-12-31	Skr10.55	Skr143.20	x
2004-12-31	Skr8.96	Skr143.20	x
2005-12-31	Skr10.46	Skr143.20	x
2006-12-31	Skr8.02	Skr143.20	x
2007-12-31	Skr8.95	Skr143.20	x
2008-12-31	Skr12.71	Skr143.20	x
2009-12-31	Skr12.34	Skr143.20	x
2010-12-31	Skr6.80	Skr143.20	x
2011-12-31	Skr7.22	Skr143.20	x
2012-12-31	Skr7.25	Skr143.20	x
2013-12-31	Skr7.00	Skr143.20	x
2014-12-31	Skr7.77	Skr143.20	x
2015-12-31	Skr8.45	Skr143.20	x
2016-12-31	Skr8.70	Skr143.20	x
2017-12-31	Skr9.40	Skr143.20	x
2018-12-31	Skr10.85	Skr143.20	x
2019-12-31	Skr13.43	Skr143.20	x
2020-12-31	Skr15.18	Skr143.20	x
2021-12-31	Skr20.96	Skr143.20	x
2022-12-31	Skr24.73	Skr143.20	x
2023-12-31	Skr49.42	Skr143.20	x
2024-12-31	Skr51.35	Skr143.20	x

Capital Efficiency Dashboard

This dashboard shows how efficiently Biotage AB utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.

Capital Efficiency Insights

Current Return on Equity (ROE): 6.90%
The company has moderate efficiency in generating returns from equity.
DuPont Analysis Breakdown:
• Net Profit Margin: 13.81%
• Asset Turnover: 0.40x
• Equity Multiplier: 1.24x
Recent ROE (6.90%) is above the historical average (2.87%), indicating improving capital efficiency.

Historical Capital Efficiency Metrics

Year	Return on Equity	Net Profit Margin	Asset Turnover	Equity Multiplier	Economic Value Added
2002	-27.33%	-172.55%	0.14x	1.10x	Skr-229.99 Million
2003	-40.10%	-140.74%	0.21x	1.36x	Skr-305.35 Million
2004	-21.99%	-31.37%	0.53x	1.33x	Skr-167.33 Million
2005	-5.40%	-9.27%	0.44x	1.32x	Skr-113.72 Million
2006	0.40%	0.54%	0.57x	1.29x	Skr-68.43 Million
2007	12.48%	20.02%	0.50x	1.24x	Skr19.75 Million
2008	26.59%	77.62%	0.30x	1.15x	Skr186.57 Million
2009	1.24%	3.42%	0.32x	1.13x	Skr-95.42 Million
2010	-72.23%	-95.64%	0.62x	1.22x	Skr-467.04 Million
2011	5.76%	7.58%	0.61x	1.24x	Skr-23.91 Million
2012	7.22%	8.28%	0.71x	1.23x	Skr-14.75 Million
2013	8.68%	9.31%	0.75x	1.24x	Skr-6.29 Million
2014	10.17%	10.42%	0.79x	1.23x	Skr847.00K
2015	13.40%	12.00%	0.91x	1.22x	Skr18.59 Million
2016	16.48%	13.89%	0.96x	1.23x	Skr36.47 Million
2017	22.80%	18.55%	0.99x	1.24x	Skr77.89 Million
2018	23.87%	18.40%	0.91x	1.43x	Skr97.41 Million
2019	21.34%	16.96%	0.82x	1.53x	Skr99.27 Million
2020	17.68%	16.02%	0.76x	1.45x	Skr76.00 Million
2021	14.94%	16.64%	0.62x	1.45x	Skr67.80 Million
2022	16.37%	17.11%	0.67x	1.43x	Skr104.30 Million
2023	6.73%	13.21%	0.38x	1.35x	Skr-119.70 Million
2024	6.90%	13.81%	0.40x	1.24x	Skr-127.30 Million

Industry Comparison

This section compares Biotage AB's net assets metrics with peer companies in the Medical Instruments & Supplies industry.

Industry Context

Industry: Medical Instruments & Supplies
Average net assets among peers: $298,794,000
Average return on equity (ROE) among peers: -83.50%

Peer Company Comparison

Company	Net Assets	Return on Equity	Debt-to-Equity	Market Cap
Biotage AB (BIOT)	Skr3.85 Billion	-27.33%	0.22x	$1.23 Billion
ADDvise Group AB A (ADDV-A)	$492.87 Million	16.45%	2.99x	$4.23 Million
ADDvise Group B (ADDV-B)	$9.65 Million	-37.27%	6.03x	$108.58 Million
AddLife AB (publ) (ALIF-B)	$1.48 Billion	9.52%	1.22x	$2.01 Billion
Bio-Works Technologies AB (BIOWKS)	$22.41 Million	-55.16%	0.10x	$34.55 Million
Bonesupport Holding AB (BONEX)	$34.30 Million	-321.22%	4.50x	$1.54 Billion
Dynavox Group (DYVOX)	$602.40 Million	27.51%	3.11x	$834.96 Million
iZafe Group AB Series B (IZAFE-B)	$25.35 Million	-126.91%	0.37x	$14.11 Million
Ortivus AB ser. A (ORTI-A)	$8.75 Million	-182.84%	2.99x	$375.76K
Ortivus AB ser. B (ORTI-B)	$17.21 Million	-81.59%	1.14x	$17.78 Million

About Biotage AB

ST:BIOT Sweden Medical Instruments & Supplies

Market Cap

$1.23 Billion

Skr11.46 Billion SEK

Market Cap Rank

#7993 Global

#122 in Sweden

Share Price

Skr143.20

Change (1 day)

+0.00%

52-Week Range

Skr143.20 - Skr143.20

All Time High

Skr280.87